'The release of primary end points is due 4th qtr. We are expecting sometime mid Oct. but it could be somewhat after that. At any rate our consensus is that barring any additional convertion by holders this could move to between 1 and 3, dollars that is, quite easily. We do expect a slow crawl up as we approach 4 qtr. Looking forward to FDA approval we are looking at 10.00 easy. We continue to accumulate. I am in FL right now and will be talking to an investor $$$$$ and good friend of mine who eagerly awaits my comments on GETA. He will take my comments to his friends $$$$$ as well. We are loading on GETA and continue to build a good chunk. Looking for results in the fall. Took starter positions in GNBT and CTIC. Talking to our folks in DC area and Florida for their take. No clear picture on GNBT but we are trying to get it. CTIC looks like a winner from here. CTICs target is April for the FDA answer. Bouncing both against our Med contact in PA."
Posts: 134 | Registered: Dec 2006
| IP: Logged |
posted
The problem here is that GETA has very limited $$$ and that Melanoma drug was the key to GETA's future.
Although there could be a small technical move higher, I'd steer clear of this stock. The future doest look too good.
Posts: 7 | Registered: Oct 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
